Drug intelligence / Profile preview

PSB103

Development stage: Unknown
Lead developer: Qilu Puget Sound Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PSB103 is a monoclonal antibody developed by Sound Biologics that targets the Programmed Cell Death Protein 1 (PD-1) receptor. It functions as an immune checkpoint inhibitor by blocking the PD-1 signaling pathway, which tumors often exploit to evade immune detection. By preventing the binding of PD-1 to its ligands, PD-L1 and PD-L2, PSB103 restores the ability of cytotoxic T cells to recognize and eliminate cancer cells. The drug is currently in Phase 2 development for the treatment of various malignancies.

Other names: pSB103pSB-103pSB 103

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on PSB103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSB103.

Explore the full profile